Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Rehearsal Lp(a) webinar
Monday, October 25, 2021 · 11:00 a.m. · Stockholm
About This Webinar
Epidemiological and mendelian randomization studies have demonstrated lipoprotein(a) to be an independent risk factor for myocardial infarction and stroke. Lipoprotein(a) consists of a specific apolipoprotein(a) that is highly heritable and bound to LDL-C particles. Recent research has increased the understanding of Lipoprotein(a) in disease and new therapies are emerging.
In this webinar speakers will review the current knowledge on lipoprotein(a) from human genetics to atherogenic mechanisms and emerging drug treatment targeting lipoprotein (a).
Agenda
- Introduction of topic. Stefano Romeo
- Potential mechanisms for the atherogenic and thrombotic effect of Lp(a). Alexandros Tselepis
- From epidemiology to human genetic studies, to define the risk of Lp(a) related CVD disease. Pia Rörbaek-Kamstrup
- Family screening and drugs targeting Lp(a) for CVD prevention. Massimiliano Ruscica
- Q&A
Who can view: Everyone
Webinar Price: Free
Featured Presenters
Chair, Professor Emeritus
Olov Wiklund is a Professor Emeritus at the Sahlgrenska Academy, at the University of Gothenburg, and previously head of the Department of Cardiology at Sahlgrenska University Hospital and head of the Wallenberg Laboratory for Cardiovascular research in Gothenburg.
He was a member of the writing group for the EAS/ESC Guidelines for dyslipidaemia 2016 and 2019. He is a previous vice-president of EAS and has held several positions in national and international organizations in the field of atherosclerosis and cardiovascular prevention. His main research interest is dyslipidaemia in cardiovascular disease with a focus on the interaction between lipoproteins and the vascular wall as well as treatment and prevention. He is currently editor for the EAS ACADEMY.
He was a member of the writing group for the EAS/ESC Guidelines for dyslipidaemia 2016 and 2019. He is a previous vice-president of EAS and has held several positions in national and international organizations in the field of atherosclerosis and cardiovascular prevention. His main research interest is dyslipidaemia in cardiovascular disease with a focus on the interaction between lipoproteins and the vascular wall as well as treatment and prevention. He is currently editor for the EAS ACADEMY.
Associate professor of General Pathology at Università degli Studi di Milano, Milan, Italy
MD PhD, Head of Department at the Department of Clinical Biochemistry, Copenhagen University Hospital – Herlev and Gentofte, Denmark
Hosted By
Attended
(6)
Recommended